(Q84171271)
Statements
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution (English)
Jason Law
Christopher C Dvorak
Lisa Musick
Janel R Long-Boyle
Lee Ann Baxter-Lowe